Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) Sees Large Decrease in Short Interest

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) was the target of a large decrease in short interest during the month of June. As of June 15th, there was short interest totalling 47,353,700 shares, a decrease of 14.0% from the May 31st total of 55,038,700 shares. Based on an average daily trading volume, of 2,945,900 shares, the days-to-cover ratio is presently 16.1 days.

Northwest Biotherapeutics Stock Performance

OTCMKTS NWBO traded down $0.02 during trading hours on Monday, hitting $0.41. The company had a trading volume of 3,791,105 shares, compared to its average volume of 1,721,718. The firm has a 50 day simple moving average of $0.46 and a 200 day simple moving average of $0.54. Northwest Biotherapeutics has a 52 week low of $0.40 and a 52 week high of $1.09. The firm has a market capitalization of $503.98 million, a price-to-earnings ratio of -6.10 and a beta of -0.57.

Northwest Biotherapeutics (OTCMKTS:NWBO) last posted its quarterly earnings data on Friday, May 10th. The biotechnology company reported ($0.02) earnings per share for the quarter. The company had revenue of $0.28 million for the quarter.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.